{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:49:48Z","timestamp":1783529388972,"version":"3.55.0"},"reference-count":38,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title>\n                  <jats:p>Human papillomavirus is the most common sexually transmitted infection in the United States and causes certain anogenital and oropharyngeal cancers. The 9-valent human papillomavirus vaccine (9vHPV) provides protection against additional types not included in the quadrivalent vaccine. We conducted near real-time vaccine safety surveillance for 24 months after the vaccine became available in the Vaccine Safety Datalink.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>Immunizations and adverse events were extracted weekly from October 2015 to October 2017 from standardized data files for persons 9 to 26 years old at 6 Vaccine Safety Datalink sites. Prespecified adverse events included anaphylaxis, allergic reaction, appendicitis, Guillain-Barr\u00e9 syndrome, chronic inflammatory demyelinating polyneuropathy, injection site reaction, pancreatitis, seizure, stroke, syncope, and venous thromboembolism. The observed and expected numbers of events after 9vHPV were compared weekly by using sequential methods. Both historical and concurrent comparison groups were used to identify statistical signals for adverse events. Unexpected signals were investigated by medical record review and\/or additional analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>During 105 weeks of surveillance, 838\u2009991 doses of 9vHPV were administered. We identified unexpected statistical signals for 4 adverse events: appendicitis among boys 9 to 17 years old after dose 3; pancreatitis among men 18 to 26 years old; and allergic reactions among girls 9 to 17 years old and women 18 to 26 years old after dose 2. On further evaluation, which included medical record review, temporal scan analysis, and additional epidemiological analyses, we did not confirm signals for any adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>After 2 years of near real-time surveillance of 9vHPV and several prespecified adverse events, no new safety concerns were identified.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2019-1808","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:24:15Z","timestamp":1574083455000},"source":"Crossref","is-referenced-by-count":47,"title":["Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine"],"prefix":"10.1542","volume":"144","author":[{"given":"James G.","family":"Donahue","sequence":"first","affiliation":[{"name":"Marshfield Clinic Research Institute, Marshfield, Wisconsin;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burney A.","family":"Kieke","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Institute, Marshfield, Wisconsin;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin M.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California, Oakland, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Weintraub","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla E.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Institute, Marshfield, Wisconsin;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"McClure","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Institute, Marshfield, Wisconsin;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Vickers","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Institute, Marshfield, Wisconsin;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Gee","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Daley","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Colorado, Aurora, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"DeStefano","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulin C.","family":"Hechter","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California, Pasadena, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P.","family":"Klein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California, Oakland, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Naleway","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Belongia","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Institute, Marshfield, Wisconsin;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2019,12,1]]},"reference":[{"key":"2021121018370462100_B1","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"2021121018370462100_B2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jnci\/djs491","article-title":"Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels","volume":"105","author":"Jemal","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2021121018370462100_B3","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"issue":"50","key":"2021121018370462100_B4","first-page":"1705","article-title":"Recommendations on the use of quadrivalent human papillomavirus vaccine in males\u2013Advisory Committee on Immunization Practices (ACIP), 2011","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"2021121018370462100_B5","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"2021121018370462100_B6","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"issue":"49","key":"2021121018370462100_B7","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"32","key":"2021121018370462100_bib39","first-page":"698","article-title":"Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR"},{"issue":"10108","key":"2021121018370462100_B8","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"issue":"48","key":"2021121018370462100_B9","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"key":"2021121018370462100_B10","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1542\/peds.2010-1722H","article-title":"The Vaccine Safety Datalink: a model for monitoring immunization safety","volume":"127","author":"Baggs","year":"2011","journal-title":"Pediatrics"},{"issue":"46","key":"2021121018370462100_B11","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"2021121018370462100_B12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/pds.2133","article-title":"Near real-time vaccine safety surveillance with partially accrued data","volume":"20","author":"Greene","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021121018370462100_B13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2334-9-165","article-title":"Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study","volume":"9","author":"Jackson","year":"2009","journal-title":"BMC Infect Dis"},{"issue":"10","key":"2021121018370462100_B14","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/MLR.0b013e3180616c0a","article-title":"Real-time vaccine safety surveillance for the early detection of adverse events","volume":"45","author":"Lieu","year":"2007","journal-title":"Med Care"},{"issue":"6","key":"2021121018370462100_B15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1311738","article-title":"Risk of intussusception after monovalent rotavirus vaccination","volume":"370","author":"Weintraub","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2021121018370462100_B16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amepre.2011.04.004","article-title":"H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project","volume":"41","author":"Lee","year":"2011","journal-title":"Am J Prev Med"},{"issue":"1","key":"2021121018370462100_B17","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"issue":"2","key":"2021121018370462100_B18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/aje\/kws317","article-title":"Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study","volume":"177","author":"Nelson","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"25","key":"2021121018370462100_B19","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.vaccine.2014.03.063","article-title":"Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine","volume":"32","author":"Daley","year":"2014","journal-title":"Vaccine"},{"issue":"32","key":"2021121018370462100_B20","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1016\/j.vaccine.2009.05.036","article-title":"An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink","volume":"27","author":"Yih","year":"2009","journal-title":"Vaccine"},{"key":"2021121018370462100_B21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/07474946.2011.539924","article-title":"A maximized sequential probability ratio test of drug and vaccine safety","volume":"30","author":"Kulldorff","year":"2011","journal-title":"Seq Anal"},{"issue":"2","key":"2021121018370462100_B22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/sim.3780","article-title":"A conditional maximized sequential probability ratio test for pharmacovigilance","volume":"29","author":"Li","year":"2010","journal-title":"Stat Med"},{"key":"2021121018370462100_B23","unstructured":"Lewis\u2008E, Fireman\u2008B, Klein\u2008NP, Baxter\u2008R. Exact sequential analysis for vaccine safety surveillance. In: Proceedings from the NFID 12th Annual Conference on Vaccine Research; April 27\u201329, 2009"},{"issue":"27","key":"2021121018370462100_B24","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1016\/j.vaccine.2012.04.040","article-title":"An efficient statistical algorithm for a temporal scan statistic applied to vaccine safety analyses","volume":"30","author":"McClure","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"2021121018370462100_B25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/10543406.2015.1052819","article-title":"Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety","volume":"26","author":"Li","year":"2016","journal-title":"J Biopharm Stat"},{"issue":"8","key":"2021121018370462100_B26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121018370462100_B27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5694\/j.1326-5377.2011.tb04138.x","article-title":"Syncope and seizures following human papillomavirus vaccination: a retrospective case series","volume":"194","author":"Crawford","year":"2011","journal-title":"Med J Aust"},{"issue":"12","key":"2021121018370462100_B28","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archpediatrics.2012.1451","article-title":"Safety of quadrivalent human papillomavirus vaccine administered routinely to females","volume":"166","author":"Klein","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"9","key":"2021121018370462100_B29","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/INF.0000000000000793","article-title":"An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015","volume":"34","author":"Vichnin","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"2021121018370462100_B30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12026-016-8823-9","article-title":"Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry","volume":"65","author":"Bizjak","year":"2017","journal-title":"Immunol Res"},{"issue":"3","key":"2021121018370462100_B31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5694\/j.1326-5377.2008.tb01960.x","article-title":"Pancreatitis following human papillomavirus vaccination","volume":"189","author":"Das","year":"2008","journal-title":"Med J Aust"},{"issue":"7","key":"2021121018370462100_B32","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"2021121018370462100_B33","first-page":"1","volume-title":"Gardasil 9","author":"US Food and Drug Administration","year":"2014"},{"issue":"2","key":"2021121018370462100_B34","doi-asserted-by":"crossref","first-page":"e20154387","DOI":"10.1542\/peds.2015-4387","article-title":"Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials","volume":"138","author":"Moreira","year":"2016","journal-title":"Pediatrics"},{"issue":"17","key":"2021121018370462100_B35","first-page":"457","article-title":"Syncope after vaccination\u2013United States, January 2005-July 2007","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2021121018370462100_B36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.vaccine.2015.10.006","article-title":"Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011","volume":"34","author":"Naleway","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"2021121018370462100_B37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3414\/ME0500","article-title":"Predictive value of ICD-9-CM codes used in vaccine safety research","volume":"47","author":"Mullooly","year":"2008","journal-title":"Methods Inf Med"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2019-1808\/1078755\/peds_20191808.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2019-1808\/1078755\/peds_20191808.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T05:29:09Z","timestamp":1639200549000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/144\/6\/e20191808\/37919\/Near-Real-Time-Surveillance-to-Assess-the-Safety"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,12,1]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2019-1808","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,1]]},"article-number":"e20191808"}}